1. Home
  2. MCRB vs HIT Comparison

MCRB vs HIT Comparison

Compare MCRB & HIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • HIT
  • Stock Information
  • Founded
  • MCRB 2010
  • HIT 1964
  • Country
  • MCRB United States
  • HIT United States
  • Employees
  • MCRB N/A
  • HIT N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • HIT Specialty Insurers
  • Sector
  • MCRB Health Care
  • HIT Finance
  • Exchange
  • MCRB Nasdaq
  • HIT Nasdaq
  • Market Cap
  • MCRB 165.3M
  • HIT 150.6M
  • IPO Year
  • MCRB 2015
  • HIT 2024
  • Fundamental
  • Price
  • MCRB $17.23
  • HIT $2.92
  • Analyst Decision
  • MCRB Hold
  • HIT Strong Buy
  • Analyst Count
  • MCRB 4
  • HIT 1
  • Target Price
  • MCRB $73.67
  • HIT $2.50
  • AVG Volume (30 Days)
  • MCRB 245.5K
  • HIT 466.0K
  • Earning Date
  • MCRB 11-12-2025
  • HIT 11-16-2025
  • Dividend Yield
  • MCRB N/A
  • HIT N/A
  • EPS Growth
  • MCRB N/A
  • HIT N/A
  • EPS
  • MCRB 10.22
  • HIT 0.02
  • Revenue
  • MCRB N/A
  • HIT $26,692,318.00
  • Revenue This Year
  • MCRB N/A
  • HIT $70.02
  • Revenue Next Year
  • MCRB N/A
  • HIT $63.39
  • P/E Ratio
  • MCRB $1.68
  • HIT $141.31
  • Revenue Growth
  • MCRB N/A
  • HIT 29.68
  • 52 Week Low
  • MCRB $6.53
  • HIT $0.51
  • 52 Week High
  • MCRB $24.67
  • HIT $7.59
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 52.55
  • HIT 56.39
  • Support Level
  • MCRB $17.00
  • HIT $2.57
  • Resistance Level
  • MCRB $24.67
  • HIT $2.89
  • Average True Range (ATR)
  • MCRB 1.79
  • HIT 0.24
  • MACD
  • MCRB -1.40
  • HIT -0.05
  • Stochastic Oscillator
  • MCRB 69.86
  • HIT 81.60

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

Share on Social Networks: